Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy

Trial Profile

Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Dec 2014

At a glance

  • Drugs Ixmyelocel-T (Primary)
  • Indications Alveolar bone loss
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 31 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top